Abstract
Objectives To evaluate the cost effectiveness of an asymptomatic SARS-CoV-2 whole area testing pilot.
Design Epidemiological modelling and cost effectiveness analysis.
Setting The community of Merthyr Tydfil County Borough between20 Nov and 21 Dec 2020.
Participants A total of 33,822 people tested as part of the pilot in Merthyr Tydfil County Borough, 712 of whom tested positive by lateral flow test and reported being asymptomatic.
Main outcome measures Estimated number of cases, hospitalisations, ICU admissions and deaths prevented, and associated costs per quality-adjusted life years (QALYs) gained and monitory cost to the healthcare system.
Results An initial conservative estimate of 360 (95% CI: 311 - 418) cases were prevented by the mass testing, representing a would-be reduction of 11% of all cases diagnosed in Merthyr Tydfil residents during the same period. Modelling healthcare burden estimates that 24 (16 - 36) hospitalizations, 5 (3 - 6) ICU admissions and 15 (11 - 20) deaths were prevented, representing 6.37%, 11.1% and 8.19%, respectively of the actual counts during the same period. A less conservative, best-case scenario predicts a much higher number of cases prevented of 2328 (1761 - 3107), representing 80% reduction in would-be cases. Cost effectiveness analysis indicates 108 (80 - 143) QALYs gained, an incremental cost ratio of £2,143 (£860-£4,175) per QALY gained and net monetary benefit of £6.2m (£4.5m-£8.4m). In the less conservative scenario, the net monetary benefit increases to £15.9m (£12.3m-£20.5m).
Conclusions A significant number of cases, hospitalisations and deaths were prevented by the mass testing pilot. Considering QALYs lost and healthcare costs avoided, the pilot was cost-effective. These findings suggest mass testing with LFDs in areas of high prevalence (>2%) is likely to provide significant public health benefit. It is not yet clear whether similar benefits will be obtained in low prevalence settings.
What is already known on this topic
As part of the UK nations’ strategies for controlling COVID-19, mass testing by lateral flow devices (LFD) has been widely used to identify asymptomatic SARS-CoV-2 infections in the community and thus reduce prevalence
This approach has proved controversial with concerns expressed about sensitivity and predictive positive value of the LFD, and about whether their use in mass testing programmes is a cost effective way of controlling COVID-19
Merthyr Tydfil Borough has had some of the highest rates of SARS-CoV-2 infection in the United Kingdom, and a mass asymptomatic testing pilot was introduced in an attempt to reduce community transmission.
The cost of mass testing with LFD has been predicted to be high, but there are little data indicating effectiveness or cost-effectiveness in terms of healthcare costs averted and quality life years (QALYs) gained.
What this study adds
We estimate that during the mass testing pilot in Merthyr Tydfil a significant number of cases, hospitalisations and deaths, that would otherwise have occurred, were prevented.
This may have contributed to a subsequent decline in disease burden in the area in early 2021
In high prevalence settings, mass testing by LFD appears to be highly cost effective when considering healthcare costs averted and QALYs gained.
Competing Interest Statement
Dr Collins is seconded as Head of Health Economics in Welsh Government, this paper does not represent any views of Welsh Government.
Funding Statement
This study was performed as part of our ongoing epidemic response and no external sources of funding were used.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed by the Public Health Wales Research and Development Office and determined to be usual practice in public health, and therefore did not require external NHS ethics committee approval. Investigation of communicable disease outbreaks and surveillance of notifiable disease is permitted under Public Health Wales Establishment Order. Data were held and processed under Public Health Wales information governance arrangements in compliance with the Data Protection Act, Caldicott Principles and Public Health Wales guidance on the release of small numbers. No data identifying protected characteristics of an individual were released outside Public Health Wales.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Aggregated data on Covid-19 cases, hospitalizations and deaths is available on the Public Health Wales Rapid Covid-19 Surveillance Dashboard. Further anonymized data can be made available on reasonable request.